Merrimack Pharmaceuticals Inc. to Present Preclinical Data at the 2013 American Association for Cancer Research-National Cancer Institute-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/15/2013 9:38:48 AM
CAMBRIDGE, Mass., Oct. 15, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present preclinical research on two novel potential cancer therapies, MM-398 and MM-141, and an innovative platform for biomarker analysis at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference will take place on October 19-23, 2013 at the Hynes Convention Center in Boston, Massachusetts. Presentations will include preclinical studies of MM-398, a nanolipsomal encapsulated form of irinotecan, and MM-141, a bispecific antibody co-targeting IGF-1R and ErbB3, and their activity in tumor models. Data will be shared in three poster sessions.
Help employers find you! Check out all the jobs and post your resume.